clinical-trials
59 stories tagged "clinical-trials"
The Ultrasound REM Patch Study Saved the Stimulation Night for Last, Every Time
Every volunteer slept a sham night first and the ultrasound night second, and an unfamiliar lab bed on its own tends to delay and shrink REM on the first night, then ease by the second.
CancerAfter 16 Years of 'Talk to Your Doctor,' the American Cancer Society Tells Men 50 to 69 to Get a PSA Test
Distant-stage prostate cancer is rising 6 percent a year in men 55 and older, and the long screening trials now show deaths prevented. The cancer society moved. The federal task force has not.
Drugs & FDAFDA Fast-Tracks a J&J Head and Neck Cancer Drug on Tumor Shrinkage, and Its Announcement Names No Confirmatory Trial
Tumors shrank in 42 percent of patients in a 102-person trial with no control arm. The FDA says clinical benefit is unconfirmed and confirmatory studies are required, and its announcement does not name one.
Drugs & FDAEdwards' Case for Earlier Heart Valves Rests on Hospital Stays, Not Survival
Edwards' own trial halved the share of moderate aortic stenosis patients hospitalized for heart failure, but deaths ran 8.4 percent with early TAVR versus 7.3 percent under initial surveillance, and 57.4 percent of that arm got the valve within two years anyway.
Brain & AgingCochrane's Cannabis-for-Insomnia Verdict: Maybe Eight More Minutes of Sleep, Maybe 23 Fewer
Across six placebo-controlled insomnia trials, medical cannabis added an estimated eight minutes of sleep, with an interval stretching from 23 minutes lost to 38 gained. Side effects were the sharper signal.
InvestigationsArgentina Logged 32 Violations in Pfizer's Maternal RSV Trial 20 Months Before the FDA Approved It for Pregnancy
Inspectors found a 16-year-old enrolled under a protocol that required women 18 or older in Argentina, and newborn serious events misclassified or left out of hospital charts. The fine came two years after approval.
Nutrition & FoodThe Peanut 'Brain Benefit' Is a Weaker Insulin Response in One Tiny Patch of Tissue
Peanut Institute money paid for a trial in which, after daily peanuts, one 552-cubic-millimeter brain cluster responded less to insulin. Liver fat and fasting blood sugar markers stayed unchanged.
CancerThe Lymphoma Combination With an 'Acceptable Safety Profile' Lost to Its Control Arm
Some oncologists want second opinions to stop steering patients away from trials. Vinay Prasad answered with venetoclax: in its randomized double-hit lymphoma cohort, estimated two-year survival was 52 percent with the drug and 72 percent without it.
Infectious DiseasePfizer's Only Placebo-Controlled Trial of Its COVID Shot in Pregnancy Never Dosed a Woman Before 24 Weeks
Pfizer announced a 4,000-woman pregnancy trial, randomized 348, dosed none of them before 24 weeks and followed their babies for six months. Vaccine mRNA has since turned up in placenta and breast milk.
Brain & AgingIf You Feel Fine, the Scientists Studying This Alzheimer's Blood Marker Say Skip the Test
Cognitively unimpaired adults with the highest p-tau217 levels had an estimated 38 percent five-year risk of cognitive impairment. The researchers won't recommend testing people without symptoms. Lilly's prevention trial used the marker to screen 63,124.
Metabolic & WeightA Very-Low-Calorie Diet and Supervised Training Put 54% of Young Adults With Type 2 Diabetes Into Remission
In a randomized trial of adults aged 18 to 45, 27 of 50 reached remission off glucose-lowering drugs at 24 weeks, against 2 of 46 on usual care. Six months is as far as the data go.
Brain & AgingIn One Genetic Fifth of an Aspirin Trial, Dementia Fell 70 Percent and Bleeding Doubled
Among older adults genetically inclined toward high platelet counts, 1 percent on aspirin developed dementia versus 3.3 percent on placebo, in an exploratory reanalysis where major bleeding also ran 4.4 versus 2.1 percent.
Autoimmune & InflammationA Daily Fiber Powder Eased Knee Arthritis Pain, and People's Grip Got Stronger Too
Six weeks of inulin, a prebiotic sold by the tub, cut knee pain 1.11 points more than placebo and added 4.62 kilograms of grip strength in a Nottingham trial, while the gut hormone GLP-1 rose alongside.
CancerNorway's Own Screening Adviser Ran the Numbers: About One in 86 Screened Women Overdiagnosed
By its own adviser's estimate, Norway's mammography program overdiagnoses about one in 86 screened women, roughly three for every breast cancer death it prevents, while a 58-trial review finds early detection is no reliable stand-in for fewer deaths.
CancerRoche's KRAS Pill Beat the Older Drugs on Survival, an Endpoint Lumakras Never Won Against Chemotherapy
Median survival ran 17.7 months on divarasib and 12.0 on a control arm that was nine-tenths Lumakras, a drug whose own confirmatory trial showed no survival edge over chemotherapy.
Drugs & FDAThe PTSD Magnet Therapy Touting 68 Percent Remission Hasn't Shown Its Placebo Arm
In Wave Neuroscience's earlier sham-controlled trial, veterans on a coil built to deliver no magnetic field improved about two-thirds as much as those on active stimulation. The sham results from the trial behind its FDA clearance still haven't been posted.
Brain & AgingThe Omega-3 Trial Headlined as a Brain-Health Bust Was Built to Measure Spinal Fluid
Two years of high-dose DHA reached the spinal fluid of older adults exactly as planned. The memory scores behind the "no benefit" headlines were an exploratory outcome, and 38 percent of volunteers dropped out.
CancerCompass Plans to File a Biliary Cancer Drug Without the Survival Trial the FDA Asked For
Tovecimig plus chemotherapy shrank more biliary tract tumors than chemotherapy alone, but median survival was 8.9 months against 9.4, and 93.5 percent of the combination arm had grade 3 or worse adverse events. The FDA recommended a survival trial before filing. Compass plans to file anyway.
Drugs & FDABlood Pressure Fell Further on the Switched-Off Ear Clip Than on the Real Device
Daytime systolic pressure fell 5.50 points on a zero-current fake ear clip and 3.15 on the active device. Queen Mary's headline said the stimulation "shows potential."
CancerHengrui's Breast Cancer Drug More Than Doubled Progression-Free Survival While Severe Anemia Hit Four in Ten Patients
Trastuzumab rezetecan pushed median progression-free survival to 16.4 months from 6.8 on chemotherapy in 551 patients, all treated in China, while grade 3 or worse anemia reached 42.8 percent against 4.8 percent.
Drugs & FDASix Months Against Twelve: How Essilor's New Myopia Lens Got Called 'Twice as Fast'
Stellest 2.0's six-month numbers sat close to the original lens's one-year result from a separate trial, and a company symposium in London called that twice as fast. The children's lens is on sale abroad and has not been cleared by the FDA.
Brain & AgingPsilocybin Trial's Banked Blood Shows Parkinson's Inflammation Markers Still Lower a Month Later
Five inflammatory signals were still below baseline a month after the second psilocybin session, in blood banked from nine Parkinson's patients in an uncontrolled UCSF pilot whose investigators carry psychedelic-industry ties.
CancerThe Vitamin C Trial That Missed Its Goal and Counted 11 Deaths Against 24
Copenhagen and USC researchers gave 1,000 mg of plain vitamin C a day to people with pre-leukemic blood disorders. The mutant clones grew regardless, but over three years of follow-up 11 patients assigned to the vitamin died, against 24 assigned to placebo.
Drugs & FDAGSK's Hepatitis B Drug Got a Label That Reaches Patients It Functionally Cured About One Time in 14
Below 1,000 IU/mL of surface antigen, 26 percent of treated patients reached functional cure. Between 1,000 and 3,000, a range the FDA's label also covers, GSK's own counts work out to about 7 percent, for a weekly injection boxed for serious liver reactions and low platelets.